Regulatory Update on Capricor’s Deramiocel for Duchenne

Capricor’s Deramiocel for Duchenne: Capricor Therapeutics, which received early funding from CureDuchenne, has indicated that the FDA has decided that an Advisory Committee meeting is not warranted at this time.  Capricor’s Biologics License Application (BLA) remains under Priority Review with PDUFA target action date of August 31, 2025

Read the full press release HERE

Read the Community Letter below: